Identification of Galectin-9 (Gal-9) as a B7-H4 binding partner and characterization of their glycosylation-dependent interaction that modulates T cell signaling within a multi-ligand/receptor network
PLOS One · 2026
DOI: 10.1371/journal.pone.0355964 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Ravear Zhiqiang Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, Beijing Normal University, Beijing, China. Hauptthemen laut MEDLINE: Galectins, Signal Transduction, T-Lymphocytes, V-Set Domain-Containing T-Cell Activation Inhibitor 1. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Municipal Science and Technology Commission.
Abstract (Originalsprache)
B7-H4, a member of the B7 family, is broadly expressed on various cancer cells and has been implicated in negative immune regulation, particularly in suppressing anti-tumor immunity. However, its receptor and the mechanisms underlying its immunosuppression remain poorly understood. Here, we identify Galectin-9 (Gal-9) as a binding partner of B7-H4 and investigate its role in modulating T cell responses. We show that glycosylation within the IgC domain of B7-H4 is required for Gal-9 binding, while the N-terminal carbohydrate recognition domain (N-CRD) of Gal-9—specifically residue R65—is essential for its binding with B7-H4. In addition, several other B7 family members (B7.1, B7.2, B7-H2, and B7-DC) and immune cell surface receptors (CD28, 2B4, CD226, and SLAMF1) also bind to Gal-9 at levels comparable to those observed with B7-H4 or TIM-3. In vitro functional assays revealed that B7-H4 inhibits Gal-9-induced activation of CD28 downstream signaling and reduces Gal-9-mediated T cell death. In vivo , Gal-9 deficiency in mice resulted in an increased proportion of splenic CD4 + T cells, whereas B7-H4 deficiency produced no detectable phenotype. Moreover, B7-H4 and Gal-9 double-knockout mice showed no additive phenotype compared with Gal-9 single-knockout mice, and tumor growth following tumor cell challenge was unaffected in all three knockout models. Collectively, these findings indicate that B7-H4, Gal-9, other B7 family members, and T cell surface immune receptors form a complex regulatory network that modulates T cell activity and anti-tumor responses, with no single component exerting a dominant effect. This study provides a detailed molecular characterization of the B7-H4–Gal-9 interaction and uncovers additional Gal-9 binding partners, offering insights into the finely tuned immune regulation mediated by the B7 family.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Life Sciences, Beijing Normal University, Beijing, China.
- National Institute of Biological Sciences, Beijing, China.
- Tsinghua Institute of Multidisciplinary Biomedical Research, Tsinghua University, Beijing, China.
ORCID-Profile: Jianhua Sui
Förderung
- Beijing Municipal Science and Technology Commission
Zitieren
APA
Wang, R. Z., Yang, F., & Sui, J. (2026). Identification of Galectin-9 (Gal-9) as a B7-H4 binding partner and characterization of their glycosylation-dependent interaction that modulates T cell signaling within a multi-ligand/receptor network. PLOS One. https://doi.org/10.1371/journal.pone.0355964
Vancouver
Wang RZ, Yang F, Sui J. Identification of Galectin-9 (Gal-9) as a B7-H4 binding partner and characterization of their glycosylation-dependent interaction that modulates T cell signaling within a multi-ligand/receptor network. PLOS One. 2026. doi:10.1371/journal.pone.0355964
BibTeX
@article{Wang2026,
author = {Wang, Ravear Zhiqiang and Yang, Fang and Sui, Jianhua},
title = {Identification of Galectin-9 (Gal-9) as a B7-H4 binding partner and characterization of their glycosylation-dependent interaction that modulates T cell signaling within a multi-ligand/receptor network},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0355964}
}
EUVIMED